Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma
Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 4
Abstract
Background and rationale of the study. Effect of Long-term nucleoside/nucleotide (NUC) on hepatocellular carcinoma (HCC) incidence in a population of HBeAg-negative genotype D patients has not been adequately studied in real-life cohorts. Our aim was to evaluate the impact of liver fibrosis and other variables on HCC incidence in this population of patients. Of 745 patients with chronic hepatitis B (CHB), 306 HBeAg-negative genotype D were selected and included in this study. All patients received treatment with NUC for at least 18 months. Patients with CHB or compensated cirrhosis were included. Patients with HCC diagnosed before or during the first 18 months of NUC therapy were excluded. Results. HCC was diagnosed in 2 CHB patients (1.0%) and 23 cirrhosis patients (20%) (OR = 24.41, 95% CI 5.40 < OR < 153.2; p < 0.0001). Multivariate analysis revealed that HCC risk was independently associated with age ≥ 60 years (OR = 6.45, 95% CI 1.22 to 34.0; p = 0.02) and liver cirrhosis (OR = 12.1, 95% CI 1.39 to 106.2; p = 0.02), but not with virological response (VR), and previous resistance to NUC, or rescue therapy. Multivariate analysis in cirrhosis patients revealed that only age ≥ 60 years was an independent risk factor associated with HCC (p = 0.003). Conclusions. Liver cirrhosis and age ≥ 60 years are the stronger risk factors for HCC in genotype D HBeAgnegative patients. Previous resistance to NUC in patients that achieved a VR after rescue therapy was not a predictive factor regarding HCC. VR does not appear to significantly reduce the overall incidence of HCC when a patient has already progressed to liver cirrhosis.
Authors and Affiliations
Adriano M. Pellicelli, Pascal Vignally, Vincenzo Messina, Antonio Izzi, Ettore Mazzoni, Angelo Barlattani, Donato Bacca, Mario Romano, Fabrizio Mecenate, Tommaso Stroffolini, Caterina Furlan, Umberto V. Gentilucci, Roberto Gulminetti, Maria E. Bonaventura, Cecilia D’Ambrosio, Amerigo Paffetti, Cristina Mastropietro, Massimo Marignani, Lucia Fondacaro, Giuseppe Cerasari, Arnaldo Andreoli, Giorgio Barbarini
Keywords
Related Articles
- EP ID EP78415
- DOI -
- Views 125
- Downloads 0
Severe hepatitis induced by cyproterone acetate: role of corticosteroids. A case report
Cyproterone acetate (CPA) is an oral anti-androgen commonly used to treat advanced prostate cancer. A variety of hepatotoxic reactions has been reported with CPA. Here we describe a case of a male patient who developed s...
How to diagnose hepatic encephalopathy in the emergency department
[b]Introduction[/b]. Blood ammonia-measurements are often performed in the emergency departments to diagnose or rule out hepatic encephalopathy (HE). However, the utility and correct interpretation of ammonia levels is a...
Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C
Introduction. In patients with chronic hepatitis C it is still debated whether previous exposure to the hepatitis B virus, diagnosed from the presence of the anti-HBc antibody, is linked to a greater risk of severe hepat...
A metal mixture induces transformation upon antioxidant depletion in a hepatic cell line
[b]Introduction[/b]. Metals are ubiquitous soil, air, and water pollutants. A mixture of arsenic cadmium and lead, in particular, has commonly been found in the vicinity of smelter areas. The mixture of As-Cd-Pb has been...
Does the size of the needle influence the number of portal tracts obtained through percutaneous liver biopsy?
Aim. Liver biopsy (LB) is often essential for the diagnosis and staging of chronic viral hepatitis. The aim of our paper was to establish if the size of the biopsy needle influences the number of portal tracts obtained...